Potentially because of slowed telomere attrition and regulation of cancer-related gene expression.
ONCOLOGY
Fully funded by 
Content independently selected
-
High zinc levels tied to lower lung cancer risk in men -
ALK+ NSCLC: frontline alectinib tops crizotinib in all-Asian trial ALESIA study confirms consistency of the global ALEX trial.
-
NICE says no to osimertinib for EGFR-positive NSCLC The NICE appraisal committee raised a number of issues concerning the clinical evidence
-
NSCLC: pembrolizumab tops chemotherapy at lower PD-L1 cutoff KEYNOTE-042 data led FDA to lower the PD-L1 cutoff.
-
Stage II NSCLC: thorascopic lobectomy similarly effective to open surgery VATS offers shorter hospital stay with no significant difference in long-term survival.
-
Meta-analysis: pneumonitis rare in ALK-positive NSCLC Patients in Japan had highest incidence.
-
NSCLC: high-dose SBRT extends survival in stage II disease Benefit limited to patients with node-negative disease.
-
ECCMID 2019 - Cancer chemotherapy drives antimicrobial resistance by disrupting the gut microbiome By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.
-
ELCC 2019 - Some hints to overcoming resistance to checkpoint inhibitors The classic complement pathway has been implicated in immunomodulation of tumors of the lung
-
ELCC 2019 - Many problems with accessibility to lung cancer care in low and middle income EU countries Most health care systems in the eastern part of the EU are under financed and under equipped to deal with lung cancer
-
ELCC 2019 - In first-line nonsquamous NSCLC, patients with EGFR mutations benefit from adding atezolizumab to standard care Exploratory subgroup analysis of IMpower150 trial indicates efficacy for EGFR-mt+ patients given atezolizumab in addition to bevacizumab and standard chemotherapy
-
EGFR+ NSCLC: frontline bevacizumab-erlotinib combo delays progression Interim analysis of a multicenter phase 3 trial.
-
ELCC 2019 - Pooled data from KEYNOTE trials confirm safety and efficacy of pembrolizumab in elderly patients with NSCLC Efficacy of checkpoint-inhibitor pembrolizumab in NSCLC extends to patients beyond 75 years of age
-
ELCC 2019 - Strong intracranial efficacy emerges from combined data of entrectinib in ROS1 fusion-positive NSCLC More than half of patients with ROS1 fusion-positive NSCLC and brain metastases respond to entrectinib